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Abstract
Context
Chronic systemic inflammation in obesity originates from local immune responses in viscer-
al adipose tissue. However, assessment of a broad range of inflammation-mediating cyto-
kines and their relationship to physical activity and adipometrics has scarcely been reported
to date.
Objective
To characterize the profile of a broad range of pro- and anti-inflammatory cytokines and the
impact of physical activity and energy expenditure in individuals with general obesity, cen-
tral obesity, and non-obese subjects.
Design, Setting, and Participants
A cross-sectional study comprising 117 obese patients (body mass index (BMI) 30) and
83 non-obese community-based volunteers.
Main Outcomes Measures
Serum levels of interleukin (IL)-2, IL-4, IL-5, IL-10, IL-12, IL-13, granulocyte-macrophage
colony-stimulating factor (GM-CSF), interferon (IFN)-γ and tumor necrosis factor (TNF)-α
were measured. Physical activity and energy expenditure (MET) were assessed with acti-
graphy. Adipometrics comprised BMI, weight, abdominal-, waist- and hip-circumference,
waist to hip ratio (WHR), and waist-to-height-ratio (WHtR).
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Results
General obesity was associated with significantly elevated levels of IL-5, IL-10, IL-12, IL-13,
IFN-γ and TNF-α, central obesity with significantly elevated IL-5, IL-10, IL-12, IL-13 and
IFN-γ-levels. In participants with general obesity, levels of IL-4, IL-10 and IL-13 were signifi-
cantly elevated in participants with low physical activity, even when controlled for BMI which
was negatively associated with physical acitivity. Cytokines significantly correlated with adi-
pometrics, particularly in obese participants.
Conclusions
Results confirm up-regulation of certain pro- and anti-inflammatory cytokines in obesity. In
obese subjects, physical activity may lower levels and thus reduce pro-inflammatory effects
of cytokines that may link obesity, insulin resistance and diabetes.
Introduction
Obesity is a medical condition characterized by excessive body fat with a body mass index
(BMI) exceeding 30 kg/m2, which leads to serious impairment of health [1]. With more than
500 million people worldwide currently affected, obesity and highly co-morbid disorders like
metabolic syndrome (MetS), cardiovascular diseases, diabetes, sleep disorders and chronic in-
flammatory diseases present major health concerns in developed and developing countries [1,
2]. Former interpretations of obesity as a life-style issue simply resulting from an imbalance be-
tween energy intake and expenditure have given way to evidence of more complex and multi-
factorial pathogenic processes. Adipose tissue (AT) is not only an energy reservoir but a
multifunctional endocrine organ secreting a range of bioactive peptides and proteins [3]. These
adipocyte-derived adipokines are a heterogeneous group including cytokines, hormones,
growth factors, acute phase proteins, prostaglandins, glucocorticoids and sex steroids, with
complex effects on the receptor organs liver, pancreas, skeletal muscle, kidneys, hypothalamus
and the immune system [4]. In obesity, alterations of adipokines and several further cytokines
are thought to contribute to a low grade inflammation within the AT affecting the development
of several secondary diseases such as MetS, insulin resistance (IR), diabetes, arterial hyperten-
sion and asthma [5–7].
Changes in cytokine release are related to the infiltration of macrophages into AT that fol-
low the adipocyte-secretion of chemoattractants like tumor-necrosis-factor alpha (TNF-α) and
free fatty acids [8]. The shift in the activation state of macrophages from mainly alternatively
activated (M2) to classically activated macrophages (M1) is enhanced in obesity and controlled
by a number of cytokines. Thus, interleukin (IL)-13, and IL-4 show mainly pro-M2-properties
[9, 10], whereas interferon (IFN)-γ and granulocyte macrophage colony-stimulating factor
(GM-CSF) exhibit pro-M1-properties [11, 12]. Closely related to macrophage polarization is
the shift from T-helper cells 2 (TH2) to T-helper cells 1 (TH1) and altered activity of regulatory
T (Treg) cells in obesity [10]. In obesity, under a high-fat diet (HFD), pro-inflammatory TH1
and M1 macrophages were reported to be activated and to produce IFN-γ, TNF-α, and IL-12
[11, 13], whereas the differentiation of naïve T-cells into anti-inflammatory TH2 which secrete
IL-4, IL-10 and IL-13, as well as the activity of Treg cells, were reduced [14].
To date, in-vivo serum studies with respect to levels of serum cytokines in subjects suffering
from obesity and MetS are scarce. The secretion of pro-inflammatory adipokines by
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hypertrophied adipocytes of visceral AT, predominately TNF-α and IL-6, has been reported in-
creased in obese subjects [3, 15], whereas the secretion of anti-inflammatory adipokines seems
to be suppressed [16]. Levels of IL-12 were elevated in obesity [17], IFN-γ, IL-4, IL-5, IL-12
and IL-13 elevated in MetS [18]. Inconsistent results were found for IL-10 levels [16, 19]. In
obese adolescent girls, TNF-α, IL-4 and IL-5 levels were higher in those with central obesity
[20]. For several cytokines it has been reported that their concentrations correlate with BMI
[21, 22]. Thus, by reducing BMI and especially visceral AT, physical exercise is able to reduce
the production and circulation of pro-inflammatory mediators [23, 24].
In order to investigate the role of a broad range of pro- and anti-inflammatory cytokines in
obesity, serum levels of TNF-α, IFN-γ, IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, and GM-CSF were
compared between obese and non-obese participants. Since physical activity has been shown to
modulate weight and levels of pro-inflammatory mediators [23, 25], cytokine levels were fur-
ther combined with actigraphic assessment of activity including the amount of steps and the
determination of the ‘Metabolic Equivalent of Task (MET)’. A MET is a physiological measure
of the energy costs of physical activity and is defined as the ratio of metabolic rate during a
physical activity to a reference metabolic rate. To further elucidate the role of fat distribution,
cytokines were compared between participants with and without central obesity and correlated
with a range of adipometrics.
To our knowledge, this is the first study investigating IL-2, IL-13 and GM-CSF with regard
to central obesity and the first combining cytokine levels and objective actigraphic measures of
physical activity in obese participants. We hypothesized pro-inflammatory cytokines to be ele-
vated in obese compared to non-obese participants and in participants with central obesity
compared to those without central obesity. We further hypothesized levels of pro-inflammato-
ry cytokines to be elevated in participants with low vs. high physical activity within the
separate groups.
Materials and Methods
Participants
We recruited 240 participants of which 200 were included into final analyses: 117 obese pa-
tients (BMI 30) from the outpatient clinic of the Integrated Research and Treatment Center
for Adiposity Diseases Leipzig (IFB) and a control group of 83 non-obese (BMI< 30) volun-
teers recruited via announcements (intranet, internet, local newspapers). Without reference to
their BMI category, all 200 participants were separately categorized into with central obesity (n
= 69) and without central obesity (n = 131) groups, according to the waist-to-hip-ratio (WHR;
central obesity 0.85 in females, 0.90 in males). Thus, the without central obesity group in-
cluded the 15 participants from the obesity group with only general but not central obesity.
Evaluation of inclusion and exclusion criteria for the study was performed in two stages. First,
potential participants were contacted via phone and invited to participate in a telephone
screening interview, comprising socio-demographic data, screening for somatic disorders and
a checklist of the Structured Clinical Interview for DSM-IV [26]. Eligible participants were
then invited to the study centre, where exclusion criteria were assessed in more detail. Exclu-
sion criteria were acute or chronic infections, current medication with a recognized impact on
the immune system, psychiatric and neurological disorders, and a history of head injury with
loss of consciousness exceeding 1 hour. Assessments for current and past history of physical
and mental health problems as well as current medication were performed using standardized
forms. We also assessed co-morbidities and current medications (Table 1). All participants
were aged 18 to 70 years. Written informed consent was obtained from all participants. The
study was approved by Leipzig University Ethics Committee (#015–10–18012009).
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Clinical measurements
Qualified healthcare professionals performed all adipometric examinations. Weight [kg] was
determined in underwear and without shoes using a digital scale calibrated and standardized
using a weight of known mass. Height [cm] was recorded using a stadiometer with participants
standing on a flat surface at a right angle to the vertical board of the stadiometer. Abdominal
circumference [cm] was measured with an inelastic measuring tape placed over the skin. While
participants stood upright, circumference was taken at the level of the narrowest part of the
Table 1. Comorbidities and current medication in obese and non-obese participants.
Obese (n = 117) Non-obese (n = 83) p value (Fisher's exact test)
Comorbidities
Hypertension 55 3 < 0.001
Arthrosis 35 0 NA
Diabetes mellitus 28 0 NA
Hypothyreosis 24 4 = 0.002
Asthma 15 3 = 0.026
Cardiovascular disease 12 0 NA
Sleep apnea 7 0 NA
Steatosis hepatis 6 0 NA
Gastroesophageal reflux disease 6 0 NA
Atopic disease 5 2 = 0.702
Glaucoma 4 0 NA
Articular gout 2 0 NA
Polycystic ovary syndrome 1 0 NA
Current medication
Antihypertensives 50 3 < 0.001
Beta blockers 18 2 = 0.003
ACE Inhibitoren 20 1 < 0.001
Diuretics 25 0 NA
Calcium antagonists 5 0 NA
AT1 antagonists 13 0 NA
Alpha2 agonist 3 0 NA
Alpha1 blocker 2 0 NA
Oral antidiabetics 24 0 NA
Thyroid hormones 16 4 = 0.052
Contraceptives 11 9 = 0.813
Uricostatics 10 0 NA
NSAID 8 0 NA
Insulin 7 0 NA
Proton pump inhibitors 6 0 NA
Statins 4 0 NA
Bronchodilators 2 1 = 1.000
Nitrates 2 0 NA
Glucocorticoids 1 1 = 1.000
Vitamin K antagonists 1 0 NA
Antihistaminica 1 0 NA
Antirheumatics 1 0 NA
Opioids 1 0 NA
doi:10.1371/journal.pone.0121971.t001
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torso as seen from the anterior view. Waist circumference (WC) [cm] was measured using a
non-elastic tape at the midpoint between the last rib and the upper edge of the iliac crest at the
end of the expiratory movement. The hip circumference (HC) [cm] was also measured using a
non-elastic tape around the midline of the greater trochanter. BMI [kg/m2] was defined as
body weight [kg] divided by the square of height [m2]. WHR was defined as WC / HC. Waist-
to-height-ratio (WHtR) was defined as WC / height. All adipometric measurements were per-
formed three times and the average was used for analysis.
Cytokine measurement
After blood drawings, serum probes were immediately centrifuged at 3000 rpm for 10 min.
The supernatant was aliquoted and stored in non-absorbing polypropylene tubes of 300 μl.
Probes were shock-frozen in liquid nitrogen and stored in freezers at -80°C until further mea-
surement. Cytokines were measured using the Bio-Plex Pro human cytokine Th1/Th2 immu-
noassay from Bio Rad, Germany, a 96-well kit that includes coupled magnetic beads and
detection antibodies. This multiplex assay detects IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, GM-
CSF, IFN-γ and TNF-α.
Actigraphy
In all but 5 participants (denied participation in this part) a 1-week actigraphy recording was
performed, using the SenseWear Pro 3 actigraph (SWA; BodyMedia Inc.; Pittsburgh, Pennsyl-
vania). This device is attached to the upper right arm and records 2-axis body acceleration,
skin temperature, heat flux and galvanic skin response. Furthermore, the device detects epochs
in which it is not worn (off-wrist periods). Recordings were performed between the telephone
screening and assessment day. Participants kept a sleep and activity diary throughout the re-
cording period. Actigraphic data was analyzed using SenseWear Professional Software Version
7 (BodyMedia Inc.) for estimation of number of steps and METs per 1-minute epoch using val-
idated proprietary scoring algorithms included in the software. Several studies have demon-
strated that the SWA device provides accurate estimates of energy expenditure during rest and
activities of daily life, comparable to the gold standards of indirect calorimetry and doubly la-
beled water [27, 28]. The METs of an activity executed by an individual of a given body weight
for a specified length of time were calculated by the equation:
MET ¼ energyconsumption½kcal
bodyweight½kg  time½h
Scored data was then imported into a customized Excel template with Visual Basic for Ap-
plications (VBA) macros (Microsoft Corp.), to organize data according to sleep-wake-periods,
as follows: In the continuous data, ‘nighttime’ periods were detected based on the sleep scoring
of the SenseWear software verified by sleep log data (i.e. ‘nighttime’ comprises the duration
from first to last segment classified as sleep or laying down by the software which could be as-
signed to the nightsleep period according to the subjects sleep logs). However, ‘nighttime’ is
not equivalent to ‘nightsleep’, as subjects could be awake or get up for a certain amount of time
within the nighttime period). For daytime activity analyses, ‘days’ were not fixed to 0:00 a.m. to
11:59 p.m. but set from the middle of the preceding nighttime to the middle of the following
nighttime. Therefore, ‘daytime’ was defined as the period between two successive nighttime pe-
riods. Only ‘days’ with a minimum recording duration of 20 hours and maximum off-wrist du-
ration of 10% of the daytime period were evaluated. From the customized Excel-Template the
variables steps (= sum of steps per 1min-segment within the daytime period) and METs (= av-
erage of METs per 1min-segment within the daytime period) were taken. The two variables
Cytokine Levels in Obesity and Effects of Activity
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were calculated for 7 weekdays and averaged to obtain mean values for 1 week. Datasets were
included into analysis if they contained at least 5 days and nights of analyzable data (at least 3
week days/nights and both weekend days/nights). 140 participants fulfilled these requirements,
comprising N = 80 (57.1%) obese patients and N = 60 (42.9%) non-obese controls.
Statistics
Cytokine values were normalized using a logarithmic transformation. If cytokine levels were
lower than the detection cut-off of the immunoassay, they were assigned a value of 0. There-
fore, the following transformation formula was used: LN (cytokine value + 1). For all statistical
analyses, the LN-transformed values were used.
Differences between study participants with and without adiposity were assessed by t-tests
(age, BMI, WHR, weight, AC, WC, HC) following Gaussian distribution, and Chi2-tests (gen-
der and smoking). For correlation analyses of cytokines and adipometrics and age, Pearson
correlation coefficients were calculated. For comparisons of obese and non-obese subgroups re-
garding cytokine levels, multivariate analyses of variance with repeated measures (MANOVA)
were conducted, with levels of different cytokines representing the dependent variable and the
factor "group" (1 = obese, 0 = non-obese) being the independent variable. Main effects of the
factor "group" as well as group x cytokine level interactions were investigated. Analogously, pa-
tients with central obesity versus without central obesity had been compared. For investigations
of main effects, a post-hoc ANOVA, as well as a post-hoc ANCOVA with age as covariable,
were applied with each cytokine as a dependent variable and the respective groups (obese vs.
non-obese; with central obesity vs. without central obesity) as factors.
For cytokine differences between groups of low vs. high physical activity, ANOVAs and, in
cases of associations between age or BMI and cytokines, steps or METs (as indicated by correla-
tions |r| 0.3), ANCOVAs were calculated with age and/or BMI as covariable. Separation into
groups of high and low physical activity and high and low METs was performed by median
split of the respective variable within the total sample and the respective subgroups. The level
of significance was set at p< 0.05 for all analyses.
Table 2. Sociodemographic data and measures of obesity comparing obese and non-obese
participants.
Obese (n = 117) Non-obese (n = 83) p values
Age [years] (mean ± SD) 40.52 ± 13.26 34.20 ± 11.69 p = 0.001a
Sex (female/male) 77/40 49/34 p = 0.373b
Smoker (yes/no) 28/89 14/69 p = 0.291b
BMI [kg/m2] (mean ± SD) 44.28 ± 7.48 23.75 ± 3.02 p < 0.001a
Weight [kg] (mean ± SD) 128.74 ± 24.83 70.92 ± 12.70 p < 0.001c
Abdominal circumference [cm] (mean ± SD) 130.75 ± 18.11 85.01 ± 10.47 p < 0.001c
Waist circumference [cm] (mean ± SD) 121.65 ± 19.04 80.33 ± 10.68 p < 0.001c
Hip circumference [cm] (mean ± SD) 140.66 ± 16.15 101.07 ± 6.84 p < 0.001c
Waist-to-hip-ratio (WHR) (mean ± SD) 0.87 ± 0.10 0.79 ± 0.09 p < 0.001c
Waist-to-hight-ratio (WHtR) (mean ± SD) 0.71 ± 0.10 0.47 ± 0.05 p < 0.001c
a independent t-test,
b Chi2-test,
c Mann-Whitney-U-test.
doi:10.1371/journal.pone.0121971.t002
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Results
200 participants, 117 obese and 83 non-obese, were included in the study and analyses. Socio-
demographic differences between general obesity and non-obese groups are depicted in table 2.
The full sample was also split into groups with central obesity (n = 69) and without central obe-
sity (n = 131).
In the total sample, no cytokines showed correlations with age, whereas for IL-5, IL-10, IL-
12 and IL-13 significant weak positive correlations with all adipometrics were found. L-5 gen-
erally showed the highest correlations (r> 0.30) when compared to the other cytokines. In the
non-obese sample, significant correlations between cytokines and adipometrics were found for
IL-5 and IL-10 only. In the obese sample, IL-10, IL-12 and IL-13 showed significant weak posi-
tive correlations with all adipometrics, however, IL-5 was only associated with waist circumfer-
ence and WHtR. Also, IL-2, IL-4, IFN-γ and TNF-α exhibited significant but weak positive
associations with age. All correlation coefficients are depicted in table 3.
Comparing cytokine levels between obese and non-obese groups, the overall MANOVA
(with cytokines as repeated measures and group as factor) revealed a significant main effect of
group (F = 7.189, p = 0.008) and a groupcytokine interaction (F = 2.553, p = 0.034). Post-hoc
tests ANOVA (see table 4 left) revealed the obese group had significantly elevated serum con-
centrations of IL-5, IL-10, IL-12, IL-13, IFN-γ and TNF-α compared to the non-obese group.
Following Bonferroni correction for multiple testing, differences remained significant for IL-5,
IL-12 and IL-13.
When comparing subjects with and without central obesity the overall MANOVA revealed
a significant main effect of group (F = 7.125, p = 0.008) and groupcytokine interaction (F =
2.952, p = 0.016). In the post-hoc ANOVA (see table 4 right), subjects with central obesity
showed significantly elevated serum concentrations of IL-5, IL-10, IL-12, IL-13 and IFN-γ
compared to the group without central obesity (after Bonferroni correction, differences re-
mained significant for all but IFN-γ).
In the subsample assessed for activity levels, correlations between cytokine levels and age or
adipometrics were comparable to those found in the total sample (results not shown). Subjects
were divided into groups of high vs. low activity, assessed by median split of average number of
steps (activity) or METs (energy expenditure). Average number of steps significantly correlated
with BMI in the total sample (r = -0.556) and the obese subsample (r = -0.450) as well as with
age in obese (r = -0.306) and non-obese (r = 0.317) subsamples. Average METs correlated with
BMI in the total sample (r = -0.803), as well as the obese (r = -0.589) and the non-obese sub-
sample (r = -0.344); but for correlations with age r was below 0.30.
A MANOVA with cytokine levels as repeated measure and activity group (steps) as factor
revealed a significant main effect of activity group (F = 8.224, p = 0.005) as well as a groupcy-
tokine interaction (F = 3.077, p = 0.014). A post-hoc ANOVA (Table 5) showed a significant
decrease in cytokine levels in the active group for IL-2, IL-10, IL-12, IL-13, IFN-γ and TNF-α,
as well as a tendency for IL-4 and IL-5 (after Bonferroni correction, differences remained sig-
nificant for IL-10 and IL-13). When activity groups were compared in the subsamples, effects
were only found in the obese group. Here, the overall MANOVA again revealed a significant
main effect of activity group (F = 8.428, p = 0.005) and a significant groupcytokine interaction
(F = 3.096, p = 0.015) and the post-hoc ANOVA results showed decreased cytokine levels in
the active obese compared to the inactive obese in all cytokines but GM-CSF and IFN-γ
(Table 5). Again, after Bonferroni correction, only differences for IL-10 and IL-13
remained significant.
ANCOVAs with age and/or BMI as covariates revealed that most differences between
groups depended on the BMI. In the overall sample, differences for IL-10 remained significant
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and trended for IL-13. Within the obese subsample, differences for IL-4, IL-10, IL-13 were sig-
nificant and trended towards significance for IL-2, IL-12 and TNF-α (Table 5).
Regarding energy expenditure (METs), the overall MANOVA revealed a significant main
effect of energy group (F = 4.117, p = 0.044). Post-hoc ANOVA results showed increased levels
of IL-5, IL-10 and IL-13 in subjects with low energy expenditure in the total sample but not in
Table 3. Pearson correlations between LN-transformed cytokine levels and age and adipometrics (correlations  -0.3 and  0.3 are highlighted
in bold font).
Age [years] BMI [kg/m2] Weight [kg] AC [cm] WC [cm] HC [cm] WHR WHtR
Cytokines A r P r p r p r p r p R p r p r p
TOTAL SAMPLE
IL-2 [pg/ml] 0.126 0.075 0.143 0.044 0.152 0.032 0.127 0.082 0.155 0.028 0.127 0.074 0.115 0.105 0.146 0.040
IL-4 [pg/ml] 0.141 0.046 0.101 0.156 0.115 0.106 0.106 0.149 0.121 0.088 0.097 0.174 0.091 0.199 0.107 0.131
IL-5 [pg/ml] 0.115 0.104 0.326 <0.001 0.339 <0.001 0.320 <0.001 0.352 <0.001 0.302 <0.001 0.269 <0.001 0.340 <0.001
IL-10 [pg/ml] 0.102 0.150 0.244 <0.001 0.275 <0.001 0.291 <0.001 0.271 <0.001 0.222 0.002 0.218 0.002 0.246 <0.001
IL-12 [pg/ml] 0.062 0.381 0.284 <0.001 0.302 <0.001 0.277 <0.001 0.289 <0.001 0.248 <0.001 0.209 0.003 0.274 <0.001
IL-13 [pg/ml] 0.072 0.312 0.268 <0.001 0.294 <0.001 0.286 <0.001 0.296 <0.001 0.257 <0.001 0.215 0.002 0.276 <0.001
GM-CSF [pg/
ml]
0.120 0.090 0.140 0.049 0.117 0.098 0.156 0.032 0.144 0.042 0.113 0.112 0.106 0.137 0.153 0.030
IFN-γ [pg/ml] 0.105 0.139 0.199 0.005 0.184 0.009 0.190 0.009 0.202 0.004 0.176 0.013 0.135 0.057 0.207 0.003
TNF-α [pg/ml] 0.152 0.032 0.176 0.013 0.192 0.006 0.171 0.019 0.200 0.005 0.170 0.016 0.145 0.041 0.185 0.009
NON-OBESE SAMPLE
IL-2 [pg/ml] -0.100 0.366 0.025 0.821 0.069 0.537 0.101 0.374 0.094 0.396 -0.094 0.397 0.169 0.126 0.068 0.542
IL-4 [pg/ml] -0.098 0.376 0.046 0.679 0.101 0.364 0.096 0.399 0.091 0.411 -0.029 0.797 0.123 0.269 0.049 0.662
IL-5 [pg/ml] -0.020 0.860 0.181 0.102 0.247 0.025 0.206 0.068 0.238 0.030 0.031 0.782 0.271 0.013 0.178 0.107
IL-10 [pg/ml] -0.035 0.753 0.227 0.039 0.244 0.026 0.246 0.029 0.281 0.010 0.151 0.173 0.245 0.026 0.250 0.023
IL-12 [pg/ml] -0.060 0.593 0.137 0.216 0.170 0.123 0.081 0.478 0.152 0.170 0.046 0.680 0.154 0.165 0.111 0.317
IL-13 [pg/ml] -0.103 0.352 0.128 0.248 0.174 0.116 0.182 0.108 0.174 0.116 0.065 0.557 0.172 0.121 0.129 0.244
GM-CSF [pg/
ml]
-0.078 0.486 0.063 0.573 0.105 0.345 0.114 0.319 0.095 0.394 0.024 0.829 0.093 0.401 0.057 0.608
IFN-γ [pg/ml] -0.174 0.115 -0.010 0.927 0.072 0.519 0.062 0.588 0.052 0.639 0.012 0.917 0.051 0.647 -0.003 0.977
TNF-α [pg/ml] -0.082 0.463 0.071 0.526 0.105 0.343 0.099 0.388 0.109 0.327 -0.041 0.713 0.156 0.160 0.079 0.475
OBESE SAMPLE
IL-2 [pg/ml] 0.224 0.015 0.176 0.058 0.172 0.063 0.144 0.132 0.167 0.073 0.160 0.085 0.049 0.600 0.161 0.083
IL-4 [pg/ml] 0.265 0.004 0.125 0.179 0.129 0.166 0.145 0.131 0.141 0.130 0.129 0.167 0.049 0.599 0.131 0.158
IL-5 [pg/ml] 0.095 0.308 0.170 0.066 0.178 0.055 0.150 0.119 0.212 0.022 0.155 0.095 0.129 0.166 0.204 0.027
IL-10 [pg/ml] 0.145 0.118 0.248 0.007 0.291 0.001 0.265 0.005 0.247 0.007 0.199 0.032 0.126 0.175 0.210 0.023
IL-12 [pg/ml] 0.067 0.472 0.282 0.002 0.297 0.001 0.259 0.006 0.265 0.004 0.205 0.027 0.150 0.108 0.249 0.007
IL-13 [pg/ml] 0.127 0.171 0.232 0.012 0.272 0.003 0.236 0.013 0.271 0.003 0.219 0.018 0.143 0.123 0.243 0.008
GM-CSF [pg/
ml]
0.192 0.038 0.149 0.108 0.076 0.413 0.134 0.164 0.135 0.148 0.089 0.340 0.074 0.427 0.173 0.062
IFN-γ [pg/ml] 0.233 0.011 0.108 0.247 0.051 0.585 0.073 0.449 0.110 0.238 0.045 0.626 0.089 0.338 0.143 0.125
TNF-α [pg/ml] 0.220 0.017 0.069 0.460 0.103 0.269 0.067 0.489 0.118 0.204 0.087 0.351 0.060 0.521 0.093 0.317
BMI = Body Mass Index. AC = Abdominal circumference. WC = waist circumference. HC = hip circumference. WHR = waist-to-hip-ratio. WHtR = Waist-to-
height-ratio;
A all cytokines transformed using formula LN(X+1).
doi:10.1371/journal.pone.0121971.t003
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the two subsamples. None of these differences remained significant after Bonferroni correction
and none was significant after BMI was included as covariate (Supplement 1).
Discussion
We performed a cross-sectional investigation of serum levels of nine different cytokines in 200
participants. To the authors’ knowledge, this is the first report on IL-2, IL-13 and GM-CSF lev-
els in central obesity. Significant elevations of IL-5, IL-10, IL-12, IL-13, IFN-γ and TNF-α in
generally obese compared to non-obese were found. Looking specifically at central obesity, we
found higher levels of IL-5, IL-10, IL-12 and IL-13 and IFN-γ in participants with compared to
those without central obesity. After Bonferroni-correction, IL-5, IL-12 and IL-13 were found to
be elevated in both general and central obesity, and IL-10 elevated in the central obese. In
accordance with our hypothesis, these results provide further evidence for the presence of a
low-grade systemic inflammation in obesity, in which more than the commonly described adi-
pokines IL-1, IL-6 and TNF-α are involved.
Several mechanisms have been identified as contributing to obesity-related inflammation:
hyperplasic and hypertrophic adipocytes synthesize pro-inflammatory adipokines, macro-
phages migrate into the AT, where polarization fromM2 to M1 macrophages is enhanced [11],
whereas the TH2/ TH1 ratio and Treg cell activity is reduced [10]. These processes are suggested
to lead to a shift in cytokine levels from cytokines with anti-inflammatory properties to pro-
inflammatory cytokines in obesity. Although in-vitro and animal studies favour cytokines
secreted by M1 macrophage and TH1-cells to be up-regulated in obesity, our serum concentra-
tion data show that both M1 and M2 as well as TH1 and TH2-cytokines are likely affected in
obesity and that not only pro-inflammatory, but also anti-inflammatory cytokines, such as IL-
Table 4. LN-transformed cytokine levels compared between general obesity and non-obese participants as determined by body-mass-index
(BMI, left) and between central obesity and non-obese participants as determined by waist-hip ratio (WHR, right).
Cytokine A General Obesity determined by BMI Central Obesity determined by WHR
Non-Obese
(Mean ± SD)
Obese
(Mean ± SD)
ANOVA B (p-
value) D
ANCOVA C (p-
value) D
Obese
(Mean ± SD)
Non-Obese
(Mean ± SD)
ANOVA B (p-
value) D
ANCOVA C (p-
value) D
IL-2 [pg/ml] 1.45 ± 0.99 1.64 ± 1.15 0.2399 0.4388 1.50 ± 1.07 1.69 ± 1.13 0.2428 0.4917
IL-4 [pg/ml] 1.45 ± 0.45 1.51 ± 0.48 0.4289 0.7455 1.46 ± 0.46 1.53 ± 0.48 0.2742 0.5850
IL-5 [pg/ml] 1.02 ± 0.57 1.36 ± 0.54 < 0.0001 0.0001 1.13 ± 0.55 1.38 ± 0.60 0.0033 0.0100
IL-10 [pg/ml] 1.13 ± 1.03 1.43 ± 0.86 0.0267 0.0539 1.17 ± 0.83 1.57 ± 1.10 0.0041 0.0104
IL-12 [pg/ml] 1.89 ± 0.99 2.28 ± 0.89 0.0047 0.0072 1.96 ± 0.84 2.41 ± 1.08 0.0013 0.0020
IL-13 [pg/ml] 1.48 ± 0.81 1.78 ± 0.61 0.0031 0.0053 1.56 ± 0.67 1.85 ± 0.77 0.0051 0.0089
GM-CSF
[pg/ml]
3.34 ± 0.55 3.45 ± 0.70 0.2258 0.4055 3.34 ± 0.60 3.51 ± 0.72 0.0820 0.1902
IFN- γ [pg/
ml]
4.53 ± 0.72 4.79 ± 0.62 0.0071 0.0161 4.60 ± 0.68 4.83 ± 0.65 0.0216 0.0507
TNF-α [pg/
ml]
3.17 ± 0.58 3.39 ± 0.70 0.0194 0.0590 3.24 ± 0.61 3.40 ± 0.75 0.1043 0.2897
A all cytokines transformed using formula LN(X+1),
B ANOVA with group as factor,
C ANCOVA with group as factor and age as covariate,
D Bonferroni-Correction for Multiple Testing: α(0.05) ! p = 0.0055; α(0.01) ! p = 0.0011.
doi:10.1371/journal.pone.0121971.t004
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5, IL-13 and IL-10, show higher serum concentrations in obese participants compared to
healthy controls. These findings are supported by other studies comparing subjects with MetS
to healthy controls. In one study, M1 and M2 and TH1 and TH2-cytokines IFN-γ and IL-12
were significantly increased, as were the anti-inflammatory cytokines IL-4, IL-5 and IL-13 [18].
Overweight and obese subjects had higher levels of IL-12 than a normal-weight group, and this
Table 5. Cytokine levels in subjects with high versus low physical activity determined by average number of steps during the wake-phase.
Physical Activity determined by average number of steps
Total Sample (N = 140) Obese Sample (N = 80) Non-Obese Sample (N = 60)
Low
activity
( 8.600
steps)
High
activity
(> 8.600
steps)
ANOVA
p-values
B
ANCOVA
p-values
C
Low
activity
( 6.800
steps)
High
activity
(> 6.800
steps)
ANOVA
p-values
B
ANCOVA
p-values
D
Low
activity
(
11.000
steps)
High
activity
(>
11.000
steps)
ANOVA
p-values
B
ANCOVA
p-values E
Age 40.99 ±
14.21
36.09 ±
12.10
0.0300 - 43.58 ±
13.78
40.43 ±
12.57
0.2887 - 30.70 ±
12.00
37.13 ±
11.88
0.0413 -
BMI 41.25 ±
11.22
29.14 ±
9.62
<0. 0001 - 47.06 ±
7.82
41.16 ±
6.78
0.0005 - 23.63 ±
2.93
23.00 ±
3.01
0.4210 -
IL-2
[pg/
ml] A
1.74 ±
1.11
1.34 ±
1.09
0.0324 0.2381 1.98 ±
1.07
1.29 ±
1.19
0.0078 0.0835 1.59 ±
1.04
1.25 ±
0.99
0.1951 0.2410
IL-4
[pg/
ml] A
1.55 ±
0.52
1.41 ±
0.43
0.0817 0.3463 1.66 ±
0.57
1.36 ±
0.43
0.0076 0.0480 1.43 ±
0.41
1.42 ±
0.50
0.8608 0.9803
IL-5
[pg/
ml] A
1.27 ±
0.63
1.06 ±
0.63
0.0519 0.9819 1.48 ±
0.54
1.18 ±
0.64
0.0298 0.1315 0.85 ±
0.65
1.06 ±
0.59
0.1822 0.1603
IL-10
[pg/
ml] A
1.55 ±
1.01
1.01 ±
0.91
0.0012 0.0272 1.71 ±
0.79
1.08 ±
0.89
0.0012 0.0118 1.18 ±
1.22
1.06 ±
0.99
0.6809 0.6736
IL-12
[pg/
ml] A
2.32 ±
1.00
1.85 ±
1.02
0.0062 0.1340 2.51 ±
0.86
1.96 ±
1.06
0.0130 0.0863 1.84 ±
1.19
1.94 ±
0.94
0.7162 0.6515
IL-13
[pg/
ml] A
1.85 ±
0.66
1.46 ±
0.77
0.0017 0.0514 1.98 ±
0.65
1.55 ±
0.61
0.0029 0.0254 1.58 ±
0.64
1.43 ±
0.97
0.4870 0.5814
GM-
CSF
[pg/
ml] A
3.48 ±
0.71
3.31 ±
0.56
0.1027 0.5645 3.57 ±
0.83
3.34 ±
0.53
0.1368 0.5224 3.29 ±
0.49
3.34 ±
0.60
0.7654 0.6935
IFN-
γ
[pg/
ml] A
4.79 ±
0.59
4.53 ±
0.80
0.0306 0.3705 4.89 ±
0.66
4.67 ±
0.62
0.1203 0.4063 4.61 ±
0.47
4.37 ±
0.97
0.2204 0.3512
TNF-
α
[pg/
ml] A
3.41 ±
0.64
3.16 ±
0.65
0.0206 0.2887 3.58 ±
0.68
3.20 ±
0.64
0.0125 0.0687 3.18 ±
0.57
3.12 ±
0.57
0.6876 0.7606
A all cytokines transformed using formula LN(X+1),
B ANOVA with activity group as factor,
C ANCOVA with activity group as factor and BMI as covariate,
D ANCOVA with activity group as factor and age & BMI as covariates,
E ANCOVA with activity group as factor and age as covariate, Bonferroni-correction for Multiple Testing: α(0.05) ! p = .0055; α(0.01) ! p = .0011.
doi:10.1371/journal.pone.0121971.t005
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correlated with BMI and the grade of abdominal obesity [17]. Previous reports on IL-10 are
heterogeneous with elevated levels in obese females [19], or reduced levels in obese subjects
with either invariable concentrations in response to diet [16] or elevations associated with vis-
ceral fat loss [29]. In another study, IL-10 significantly increased, whereas TNF-α and IL-6 de-
creased following calorie restriction [30]. At the same time, anti-inflammatory IL-10 inhibited
HFD-induced weight gain, IR and glucose intolerance [31].
As further hypothesized, though only in the obese group, the finding of pro- as well as anti-
inflammatory cytokines being elevated in subjects with lower physical activity points towards a
link between exercise and cytokine levels. However, when controlled for BMI, which was highly
negatively correlated with both number of steps and METs, statistical significance was only
reached in cytokines with anti-inflammatory properties, IL-4, IL-10 and IL-13, with trends in
pro-inflammatory IL-2, IL-12 and TNF-α. Notably, the contrast between the significant differ-
ences for physical activity levels within the obese and virtually no difference within the non-
obese, remained after allowing for covariates. These findings underline the impact of BMI on
both physical activity and cytokine production. The higher BMI in the obese group with lower
activity as well as the negative correlations between BMI, steps and METs also point towards
this strong connection between BMI and physical activity that may depend on each other. The
results may further indicate a generally higher production of both anti- and pro-inflammatory
cytokines in obese participants with low activity, a pathophysiological relationship that may
not occur in normal weight subjects without bloated fat cells and boosted secretion of cyto-
kines. Congruent with these findings, the positive impact of physical activity on obesity, obesi-
ty-related diseases and inflammation has been substantiated by a large body of evidence
[25, 32], though the influence of age, BMI, or other adipometrics may also account for some
negative study results [33, 34]. The differences observed only within the obese, as well as the
generally strong relationship to BMI, may relate to the finding that exercise and diet impact on
most inflammatory mediators within AT but not within skeletal muscle [35]. Next to weight
and body mass, physical activity may further mitigate inflammation by improving endothelial
function, increasing insulin sensitivity, enhancing liver health and increasing tissue angiogene-
sis and blood flow [32, 36, 37]. Cytokine changes have also been observed in psychiatric disor-
ders associated with disturbed wakefulness regulation and altered physical activity, such as
mania and attention deficit hyperactivity disorder [38]. As a secondary finding, the discrepant
findings of a positive correlation between number of steps and age within the non-obese but a
negative correlation within the obese is worth noting and warrants further investigation. Con-
cerning energy expenditure, findings of both significantly elevated levels of cytokines with no-
tably anti-inflammatory properties IL-5, IL-10 and IL-13 within the uncontrolled total group
again lost significance when controlled for BMI, a factor which appears more closely related to
the amount of energy expenditure than the extent of cytokine production.
Concerning the device used to detect the number of steps and estimates of energy expendi-
ture and the relatively low median METs observed in the study sample, it should be noted that
mean resting energy expenditure estimated by the SWA was found to be approximately 70% of
the total energy expenditure [39]. During low and moderate activity, as observed in the majori-
ty of participants in this study, the SWA was found to provide precise estimates [40], thus pro-
viding high validity for the results presented. However, limitations of the SWA need to be
considered: the accuracies of estimates of energy expenditure are reported to depend on the
type of activity [41–44]; for example, the SWA is not able to accurately detect some everyday
activities like uphill walking, resulting in the risk of an underestimation of energy expenditure
[41, 44]. Further, several studies described an under- or overestimation of energy expenditure
by the SWA device when participants were obese or otherwise unhealthy [45–47].
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The weak but consistently positive correlations between cytokines and adipometrics, pre-
dominately found in the obese group, and for those cytokines that differed significantly in
group comparisons, suggest a relation between cytokine levels and the amount and distribution
of visceral AT. This is consistent with findings showing altered cytokine secretion to depend
on the amount of visceral rather than general obesity [20, 48]. The distribution of AT may be a
factor in alterations of cytokine levels, and may also relate obesity to highly prevalent comor-
bidities such as IR, diabetes, atherosclerosis, sleep disturbances, and asthma. The high preva-
lence of these comorbidities in obese in contrast to non-obese subjects was also apparent in our
study (Table 1).
Several studies suggest cytokines to be implicated in a common pathophysiology of obesity
and these comorbidities. For example, in pre-diabetic obese females, IL-5, TNF-α and GM-
CSF were elevated and correlated with hemoglobin A1c [49]. In contrast, deficiency of IL-5 re-
sulted in increased adiposity and IR in animals [50]. The absence of TNF-α improves insulin
receptor activity in muscle and fat tissue and reduces the amount of circulating fatty acids [51].
Accordingly, TNF-α is a stimulant for the release of free fatty acids from adipose tissue into
blood circulation and is able to decrease insulin-modulating adiponectin [52]. Recently, IL-12
was also found linked to IR by showing gene expression of IL-12 family members in insulin-
responsive tissue, such as skeletal muscle, liver, heart and white AT. The IL-12 family members
were divergently regulated in relation to excessive nutrient intake, inflammatory stress and ge-
netic obesity [53]. IFN-γ is known for its contribution to autoimmune pathologies such as
lupus erythematosus, multiple sclerosis and insulin-dependent diabetes [54–56]. Growing evi-
dence shows that there also is an autoimmune component in the pathogenesis of obesity-
related diseases like type 2 diabetes [57, 58]. Thus, IFN-γ could be involved in the pathogenesis
of obesity-linked type 2 diabetes and its progressive course. Accordingly, obese IFN-γ-knock-
out mice showed decreased adipocyte size, improved insulin-sensitivity, and a M2-shift in
macrophages and cytokine profile [59]. GM-CSF-knockout mice had both ameliorated IR and
pro-inflammatory cytokine profile [60]. For GM-CSF, evidence was given that it may influence
energy homeostasis centrally but not peripherally, since food intake and body weight were
found decreased in rodents after central GM-CSF administration [61]. GM-CSF is able to stim-
ulate differentiation of tolerogenic dendritic cells supporting Treg and secreting more IL-10.
Consistent with this, treatment of prediabetic non-obese mice with GM-CSF prevented the de-
velopment of autoimmune diabetes [62]. On the other hand, GM-CSF was found enhanced in
obese persons with prediabetes in comparison to a non-prediabetic obese control group [49].
IL-4 and IL-13 are able to generate a M2-state and disrupting M2 activation leads to obesity
and IR [63, 64]. Obesity is also a risk factor for asthma, both conditions sharing high comor-
bidity rates and asthma is more pronounced in asthmatic patients with than without obesity
[65, 7]. Inflammation in adipose tissue is able to provoke airway inflammation in multiple
ways [66, 67]. Representing heterogeneous entities, in the most phenotype of asthma, type 2
immune responses are up-regulated with elevated levels of IL-4, IL-5, IL-13 and GM-CSF
[68–70], whereas also pro-inflammatory TH1 cytokines and adipokines have been found ele-
vated [71]. In obesity-related asthma, as one of the different phenotypes in asthma, an absence
of TH2 biomarkers is often described. Thereby, obese asthmatics are less responsive to cortico-
steroid therapy [72]. In contrast and in agreement with our results for IL-5 and IL-13, TH2 par-
ticipation and more than one phenotype cluster in obese asthmatics have been postulated [73].
Therefore, further investigations are necessary to determine obese asthmatic biomarkers, es-
sential for treatment decisions, particularly because the response to conventional therapies in
“TH2 low” obese asthma is less effective.
In contrast to these potentially inflammation-derived connections between disorders, a sub-
stantial number of obese participants are not suffering frommetabolism-related disorders, called
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metabolically healthy obese, who potentially represent a variant of obese phenotypes [74]. In
these subjects, one may hypothesize predominant TH2-immunity with high levels of anti-inflam-
matory IL’s like IL-5, IL-10 and IL-13. The positive effect of physical activity on both obesity and
its related diseases, as only observed to only impact on cytokine levels within the obese, may also
lead to a down-regulation of cytokines within these subjects [23]. In future research, it might be
promising to consider the role of anti-inflammatory cytokines such as IL-5, IL-10 and IL-13 in
relation to physical activity in staying metabolically healthy despite the presence of obesity.
A number of limitations of the present work need to be addressed. Our findings do not indi-
cate whether cytokines are a cause or a consequence of obesity, nor the underlying molecular
mechanisms. Groups differed in mean age, and though this was controlled for in the statistical
analyses, matching for sex and age could increase power. Within the activity groups the BMI
needed to be included as a mandatory covariate. In future investigations homogenous sociode-
mographies and adipometrics between groups could best help to further elucidate connections
between cytokines and physical activity. The number of comorbidities differed between the
two groups and may have influenced cytokine levels. The SWA device only estimates METs
and steps and the algorithms used for calculations are proprietary and not fully open to scruti-
ny. The estimation of METs may not be accurate for the obese where energy expenditure in re-
lation to body weight, given a greater proportion of bio-inactive fat mass, is lower than for
normal weight [39]. Therefore, it would be desirable to develop obesity-specific algorithms for
the SWA, which is otherwise a reliable instrument to assess a broader range of routine daily ac-
tivity than other existing devices, like accelerometers or pedometers [75, 39].[6,69]
Conclusion
We found differences in pro- as well as anti-inflammatory cytokines when comparing 117
obese and 83 non-obese participants. Among the tested cytokines, IL-5, IL-10, IL-12, IL-13 and
IFN-γ were elevated in both general and central obesity. Physical activity modulated cytokine
production in the obese, which may have a beneficial effect in prevention of comorbidities in
obese subjects. Of the cytokines studied, IL-5 concentrations showed the strongest correlation
with adipometrics and may be a possible research and drug target in obesity. Changes in cyto-
kine concentrations may contribute to the development of secondary diseases of obesity and
may be a promising drug target in these disorders.
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